The U.S. Patent and Trademark Office has issued a Notice of Allowance for a patent covering IRLAB’s drug candidate IRL1117
Gothenburg, Sweden, October 27, 2026 – IRLAB Therapeutics AB (Nasdaq Stockholm: IRLAB A), a company focused on discovering and developing new treatments for Parkinson’s disease, today announced that the U.S. Patent and Trademark Office (USPTO) intends to grant a patent for IRL1117, a drug candidate with the potential to revolutionize the treatment of the core symptoms of Parkinson’s disease. The patent is expected to remain in force until the early 2040s.
Read More >
ISP – The proprietary technology platform
IRLAB’s unique and resource efficient research method, the Integrative Screening Process (ISP), generates the company’s drug pipeline. This proprietary platform is built on a systems pharmacology discovery approach with an extensive, world unique, standardized database on CNS compounds and classes collected over 25 years.
IRLAB’s clinical phase II candidates
Mesdopetam (IRL790)
In development to treat levodopa-induced dyskinesia (LIDs), i.e. involuntary movements occurring upon long-term treatment with levodopa in Parkinson’s disease.
Pirepemat (IRL752)
In development to treat and reduce risk of falling and falls in Parkinson’s disease.
Presentation by Kristina Torfgård, CEO, at Redeye’s Theme Event Neurology
Presentation by Kristina Torfgård, CEO, at “Theme Event Neurology”, an event hosted by Redeye, held on October 15, 2026. Link to presentation
Read More >